Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781785 | 0.86 | ALDH1A1 (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL3822835 | 0.86 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL27017174 | 0.78 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL235575 | 0.78 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13602465 | 0.77 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18854349 | 0.77 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL19100033 | 0.75 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1244569 | 0.75 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9178977 | 0.75 | GAA (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15183859 | 0.73 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6160131-A | Scalable method for the isolation of anti-HIV agents from the tropical plant calophyllum | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | GAA 270/4885MGAM 1886/4885SI 1398/4885 |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | GAA 1849/4885MGAM 2985/4885SI 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.